Dyslipidaemia rather than dysglycaemia seems to drive the changes in SHP-1 expression in animal models of obesity and diabetes as in vitro studies demonstrated that treatment with modified lipids, but not hyperglycaemia suppressed SHP-1 expression. Here, PTPN6 is linked to diabetes mellitus.